Rosuvastatin vs Protease Inhibitor Switch for Hypercholesterolemia: Randomised Trial
Background: Optimal management of hypercholesterolaemia in adults receiving a ritonavir-boosted protease inhibitor (rPI) is unknown. The two proven options, statin therapy and rPI switching to a lipid-neutral alternative, have not been compared since the advent of current-generation statins and PIs, despite multiple studies (mostly industry-sponsored) focussed upon rPI switching. Methods: Adults on rPI-based therapy with…